Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Dana-Farber Cancer Institute
AbbVie
Beth Israel Deaconess Medical Center
University of Washington
The First Affiliated Hospital with Nanjing Medical University
Fred Hutchinson Cancer Center
University of Ulm
Fudan University
Dana-Farber Cancer Institute
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
BeOne Medicines
The First Affiliated Hospital of Soochow University
International Extranodal Lymphoma Study Group (IELSG)
International Extranodal Lymphoma Study Group (IELSG)
Sun Yat-sen University
Masonic Cancer Center, University of Minnesota
Brown University
Gilead Sciences
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
University of Utah
University of Utah
Second Affiliated Hospital, School of Medicine, Zhejiang University
Memorial Sloan Kettering Cancer Center
University of Washington
Celgene
University of Washington
Regeneron Pharmaceuticals
The First Affiliated Hospital with Nanjing Medical University
University of Miami
National Taiwan University Hospital
Masonic Cancer Center, University of Minnesota
Incyte Corporation
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
The First Affiliated Hospital of Nanchang University
Second Affiliated Hospital, School of Medicine, Zhejiang University
City of Hope Medical Center
University of Miami
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
University of Washington
Hutchmed
University of Ulm